These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14621750)

  • 21. Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation.
    Knechtle SJ; Heisey DM; Pirsch JD; D'Alessandro AM; Kalayoglu M; Sollinger HW
    Surgery; 1996 Oct; 120(4):719-24. PubMed ID: 8862383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy.
    Ciancio G; Carreno M; Mathew J; Ricordi C; Garcia R; Karatzas T; Fuller L; Cirocco R; Burke G; Webb M; Nery J; Tzakis A; Roth D; Esquenazi V; Miller J
    Transplant Proc; 1996 Apr; 28(2):943-4. PubMed ID: 8623473
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
    Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
    Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
    [No Abstract]   [Full Text] [Related]  

  • 25. [The effects of the treatment for acute rejection with OKT3 monoclonal antibody treatment on the long-term results of cadaveric kidney transplantation].
    Kinukawa T; Hattori R; Ohshima S; Matsuura O; Takeuchi N; Fujita T; Nishiyama N; Ono Y; Sahashi M; Yamada S
    Nihon Hinyokika Gakkai Zasshi; 1993 Oct; 84(10):1851-6. PubMed ID: 8255049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
    Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
    Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up.
    Lyne JC; Vivas CA; Shapiro R; Scantlebury VP; Hakala TR; Starzl TE; Jordan ML
    Transplant Proc; 1997; 29(1-2):312. PubMed ID: 9123015
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
    Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
    Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of short-term OKT3 therapy in the treatment of steroid-resistant renal allograft rejection.
    Carvalho MF; Adoni T; Saggioro FP; Soares V
    Transplant Proc; 1998 Sep; 30(6):2876-7. PubMed ID: 9745607
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term results of OKT3-treated renal transplant recipients.
    Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
    Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
    Wiener Y; Nakhleh RE; Kupin WL; Lee M; Escobar FS; Venkat KK; Mozes MF
    Transplant Proc; 1995 Feb; 27(1):1014-5. PubMed ID: 7878781
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of OKT3 in steroid-resistant renal transplant rejection.
    Petrie JJ; Rigby RJ; Hawley CM; Suranyi MG; Whitby M; Wall D; Hardie IR
    Transplantation; 1995 Feb; 59(3):347-52. PubMed ID: 7871563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients.
    Birkeland SA
    Transplantation; 2001 Apr; 71(8):1089-90. PubMed ID: 11374407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C; Cristol JP; Chong G; Okamba A; Lorho R; Mion C; Mourad G
    Transpl Int; 1994; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients.
    Kliem V; Petersen R; Ehlerding G; Schaumann D; Eisenberger U; Koch KM; Pichlmayr R; Brunkhorst R
    Transplant Proc; 1998 Jun; 30(4):1251-3. PubMed ID: 9636509
    [No Abstract]   [Full Text] [Related]  

  • 38. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients.
    Peddi VR; Kamath S; Schroeder TJ; Munda R; First MR
    Transplant Proc; 1998 Mar; 30(2):285-7. PubMed ID: 9532041
    [No Abstract]   [Full Text] [Related]  

  • 40. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
    Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP
    Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.